These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19469654)

  • 21. Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
    Pellagatti A; Benner A; Mills KI; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Verma A; McDonald EJ; Killick S; Hellström-Lindberg E; Bullinger L; Wainscoat JS; Boultwood J
    J Clin Oncol; 2013 Oct; 31(28):3557-64. PubMed ID: 24002510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation.
    Hopfer O; Komor M; Koehler IS; Schulze M; Hoelzer D; Thiel E; Hofmann WK
    Exp Hematol; 2007 May; 35(5):712-23. PubMed ID: 17577921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients.
    Pereira JK; Traina F; Machado-Neto JA; Duarte Ada S; Lopes MR; Saad ST; Favaro P
    Leuk Res; 2012 Oct; 36(10):1300-3. PubMed ID: 22784712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes.
    Roela RA; Carraro DM; Brentani HP; Kaiano JH; Simão DF; Guarnieiro R; Lopes LF; Borojevic R; Brentani MM
    Leuk Res; 2007 May; 31(5):579-89. PubMed ID: 17092558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.
    Kalina U; Hofmann WK; Koschmieder S; Wagner S; Kauschat D; Hoelzer D; Ottmann OG
    Exp Hematol; 2000 Oct; 28(10):1158-63. PubMed ID: 11027834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA micro-array analysis of myelodysplastic syndrome.
    Mano H
    Leuk Lymphoma; 2006 Jan; 47(1):9-14. PubMed ID: 16321821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of EZH2 expression in myelodysplastic syndromes.
    Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
    Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purification of Bone Marrow Clonal Cells from Patients with Myelodysplastic Syndrome via IGF-IR.
    He Q; Chang CK; Xu F; Zhang QX; Shi WH; Li X
    PLoS One; 2015; 10(10):e0140372. PubMed ID: 26469401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers.
    Xu L; Gu ZH; Li Y; Zhang JL; Chang CK; Pan CM; Shi JY; Shen Y; Chen B; Wang YY; Jiang L; Lu J; Xu X; Tan JL; Chen Y; Wang SY; Li X; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8589-94. PubMed ID: 24850867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transcriptome profiling of marrow mononuclear cells of patients with myelodysplastic syndrome using cDNA microarray analysis].
    Qian J; Chen ZX; Wang W; Cen JN; Xue YQ
    Zhonghua Yi Xue Za Zhi; 2004 Aug; 84(15):1260-4. PubMed ID: 15387962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Over-expression of cancerous inhibitor of PP2A (CIP2A) in bone marrow cells from patients with a group of high-risk myelodysplastic syndromes.
    Li N; Abe S; Kurata M; Abe-Suzuki S; Onishi I; Kirimura S; Murayama T; Hidaka M; Kawano F; Kitagawa M
    Pathol Oncol Res; 2014 Apr; 20(2):399-407. PubMed ID: 24163288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications.
    Invernizzi R; Travaglino E; Della Porta MG; Malcovati L; Gallì A; Bastia R; Ciola M; Ambaglio I; Boveri E; Rosti V; Cazzola M
    Leuk Lymphoma; 2017 Jul; 58(7):1711-1720. PubMed ID: 27897450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome.
    Gueller S; Komor M; Nowak D; Baldus CD; de Vos S; Hoelzer D; Ottmann OG; Hofmann WK
    Exp Hematol; 2010 Sep; 38(9):718-32, 732.e1-6. PubMed ID: 20621626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome.
    Dostalova Merkerova M; Krejcik Z; Votavova H; Belickova M; Vasikova A; Cermak J
    Eur J Hum Genet; 2011 Mar; 19(3):313-9. PubMed ID: 21150891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
    Buccisano F; Maurillo L; Tamburini A; Del Poeta G; Del Principe MI; Ammatuna E; Consalvo MI; Campagna S; Ottaviani L; Sarlo C; Renzi D; Faccia S; Fraboni D; Lo Coco F; Amadori S; Venditti A
    Eur J Haematol; 2008 Feb; 80(2):107-14. PubMed ID: 18028430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):234-8. PubMed ID: 21418866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.
    Vaxevanis CK; Bauer M; Subbarayan K; Friedrich M; Massa C; Biehl K; Al-Ali HK; Wickenhauser C; Seliger B
    Oncoimmunology; 2023; 12(1):2152998. PubMed ID: 36531688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.